Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis by Wittebole, X. et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2010, Article ID 568396, 9 pages
doi:10.1155/2010/568396
Review Article
Toll-likeReceptor4Modulation as aStrategy to TreatSepsis
X. Wittebole,D. Castanares-Zapatero,and P. F. Laterre
Critical Care Unit, Acute Medicine Department, St Luc University Hospital, Universit´ e Catholique de Louvain, Avenue Hippocrate 10,
1200 Bruxelles, Belgium
Correspondence should be addressed to X. Wittebole, xavier.wittebole@uclouvain.be
Received 2 December 2009; Accepted 2 March 2010
Academic Editor: Philipp Lepper
Copyright © 2010 X. Wittebole et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despite a decrease in mortality over the last decade, sepsis remains the tenth leading causes of death in western countries and
one of the most common cause of death in intensive care units. The recent discovery of Toll-like receptors and their downstream
signalling pathways allowed us to better understand the pathophysiology of sepsis-related disorders. Particular attention has been
paid to Toll-like receptor 4, the receptor for Gram-negative bacteria outer membrane lipopolysaccharide or endotoxin. Since
most of the clinical trial targeting single inﬂammatory cytokine in the treatment of sepsis failed, therapeutic targeting of Toll-like
receptor 4, because of its central role, looks promising. The purpose of this paper is to focus on the recent data of various drugs
targeting TLR4 expression and pathway and their potential role as adjunctive therapy in severe sepsis and septic shock.
1.Introduction
Despite a decrease in mortality over the last decade, sepsis
remains the tenth leading causes of death in western
countries and one of the most common cause of death in
intensive care units [1]. Between 1979 and 2000, there wasan
annualised increase in the incidence of sepsis of 8.7 percent,
reaching 240.4 per 100000 people in 2000 [2]. Despite
progressinbetterrecognitionandimprovedstandardofcare,
mortality still ranges from 30 to 50% in patients with septic
shock [3]. Hence, unmet needs for those patients are still
present.
About 12 years ago, the discovery of the Toll-like recep-
tor (TLR) unravelled the missing link between endotoxin
recognitionbyLBPandCD14andtheintracellularsignalling
pathway, leading to the activation and translocation of
NFκB to the nucleus, and the subsequent production of
proinﬂammatory cytokines [4–6]. TLRs were ﬁrst described
in Drosophila melanogaster where it functions as a key
receptor for dorsoventral polarity during development and
is required for immunity against fungal infections [7]. The
toll-signalling pathway was shown to have major similarities
with the mammalian IL-1 receptor pathway. To date, 10
TLR or pattern-recognition receptors (PRRs) are identiﬁed
inhumanandaseriesofstudieshaverevealedtheirrespective
ligands [8–10]. TLRs recognize essential structures expressed
by pathogen (collectively referred to as Pathogen Associated
Molecular Patterns or PAMPS) as well as endogenous
mediators released during tissue damage, independently of
infectious state (these mediators referred to as alarmins
or Danger Associated Molecular Patterns or DAMPS). The
role of TLR and TLR signalling in the pathogenesis and
development of sepsis was recently reviewed [11–13].
In order to prevent an overwhelming activation of TLR,
and its potential side eﬀects, many natural substances modu-
late TLR expression and signalling. For instance, RP105, ini-
tially discovered in murine B cells [14], displays several sim-
ilarities with TLR; it has an extra cellular leucin-rich domain
andaTLR-likepatternofjuxtamembranecysteins;itssurface
expression depends on the cosecretion of a secreted helper
protein, in this case, MD1 [15]. However, unlike TLR, RP105
lacksanintracellulardomain.Furthermore,theextracellular
domain is a speciﬁc TLR4 homologue [16]. It therefore acts
as a physiological inhibitor of TLR4 signalling. This was
elegantly demonstrated and reviewed elsewhere [16, 17]. In
summary, the complex RP105-MD1 interacts directly with
the TLR4 signalling complex, preventing its ability to bind
LPS. It regulates TLR4 signalling in various immune cells
as well as in mice challenged with intraperitoneal E. coli
LPS. Modulation of the RP105-MD1 complex could help2 Mediators of Inﬂammation
Table 1: Some of the natural inhibitors of TLR4 signalling.
Level of action Natural TLR4 signaling
inhibitor
Extracellular
Soluble CD14 sCD14
Soluble MD2 sMD2
Soluble TLR4 sTLR4
Membrane
Receptor RP105 RP 105
TNF-Related Apoptosis
Inducing Ligand-
Receptor
TRAIL-R
Receptor ST2 ST2
Intracytoplasmic
(i) MyD88
Short form of MyD88 MyD88s
Single Immunoglobulin
Il-1 Receptor-related
molecule
SIGIRR
(ii) IRAK
Interleukin-1 receptor
associated kinase M
IRAK M
Monarch 1
Toll Interacting Protein TOLLIP
(iii) TRAF-6 A20
β-arrestin
(iv) P38 and JNK kinases Phosphatidyl inositol 3
kinase
PI3K
(v) NFκB
A20-binding inhibitor of
NFκB activation
ABIN-3
p50 and Mel B dimers
(vi) Cytokine secretion Suppressor of cytokine
secretion 1
SOCS1
abolish TLR4 overstimulation. Further clinical development
is warranted to evaluate a potential role in the treatment
of sepsis and associated clinical states. Some of the other
natural molecules aimed at controlling TLR eﬀects are listed
in Table 1.
Since lipopolysaccharide (LPS) or endotoxin is a speciﬁc
ligand for TLR4, and because TLR4 expression is increased
on human monocytes in healthy volunteers undergoing LPS
challenge [18],and in patientswithsepsis [19,20],particular
attention has been made to this receptor and signalling
pathway. The purpose of this paper is to focus on various
drugs interfering with TLR4 expression or TLR4-related
intracellular pathway and their potential role as adjunctive
therapy in severe sepsis and septic shock, or as modulator of
the TLR4-induced inﬂammatory response (Table 2).
2.AntibodiesDirectedagainstTLR4and
the TLR4-MD2 Complex
Soluble decoy receptors provide important negative reg-
ulatory mechanisms for cytokines and chemokines, and
their interaction with their membrane-bound receptor. For
instance, increased levels of soluble TNFα receptor (sTNFR)
are present up to 24 hours after an LPS challenge in healthy
volunteers and correlate with the severity of the insult in
Table 2: Mode of action of various molecules targeting TLR4.
Molecules interfering with TLR4 and TLR4-mRNA expression
(1) Chloroquine
(2) Ketamine
(3) GTS21 (nicotinic analogue)
(4) Statins
(5) Vitamin D3 (?)
(6) Lidocaine
(7) Glycine
Molecules interfering with TLR4-related intracellular signalling
pathway
(1) Eritoran (E5564)
(2) Resatorvid (TAK242)
(3) Ketamine
(4) Opioids
(5) Vitamin D3 (through its action on LL37)
(6) Lansoprazole (through its action on SOCS1)
criticallyillpatientswherelowlevelofsTNFRpredictshigher
mortality [21]. In mice, Iwami et al. were able to clone a
splice TLR4 mRNA that encodes a soluble 20-kDa protein
[22]. When expressed in Chinese ovary (CHO)-K1 cells,
this protein is secreted in the culture medium. It inhibits
LPS-mediated TNFα secretion and NFκBa c t i v a t i o ni na
mouse macrophage cell line. Interestingly, LPS stimulation
increasedthesTLR4mRNAexpression,suggestinganegative
feedback to inhibit excessive cytokine production. Any
compound able at increasing this natural soluble TLR4
would thus be of potential interest in treating patients with
sepsis.
A speciﬁc antibody raised against the ectodomain of
TLR4 was recently described [23]. In summary, a chimeric
protein composed of the N-terminal half of the mouse TLR4
ectodomain was fused to the Fc domain of human IgG1. In
the presence of soluble MD2, this protein binds LPS and
inhibits LPS-induced TNFα release in whole blood. It was
then used to generate high titres of rabbit antimouse TLR4
antibody. These antibodies were able to inhibit response of
immune cells exposed to LPS or Gram-negative bacteria in
vitro and in vivo. Furthermore, this antibody protects from
lethality in mice exposed to endotoxemia or live E. coli [23].
Another TLR4 antibody was developed [24]. The extra
cellular portion of mouse TLR4 was fused with mouse MD-2
via a 15-amino-acid ﬂexible linker. IgG Fc fragments were
added to the molecule. This molecule dose-dependently
inhibits IL-6 production in RAW 264.7 cells exposed to
LPS, and, binds to the surface of Gram-negative bacteria.
Depending on the IgG isotype, it also modulates phago-
cytosis and complement activation. Hence, this molecule
could act through 2 distinct mechanisms: on one hand,
LPS binding and decreased inﬂammatory response, and,
on the other hand improved bacterial phagocytosis and
complement mediated killing [24].
Further development is required before these molecules
could undergo clinical evaluation.Mediators of Inﬂammation 3
3. Eritoranor E5564
E5531 is a ﬁrst generation lipid A analogue, derived from the
lipid A structure from the endotoxin of Rhodobacter capsu-
latus. It blocks LPS in cell culture without any endotoxin-like
activity [25]. E5531 protects mice from lethal doses of LPS,
and viable E. coli infections in combination with antibiotics
[25]. It also blocks the endotoxin response in human healthy
volunteers exposed to intravenous LPS [26]. Some issues on
E5531, such as decreased activity over time in human blood
due to interaction with plasma lipoproteins [27, 28], led to
the search for second generation LPS antagonist (reviewed in
[29]).
Like E5531, E5564, or eritoran is a synthetic molecule,
derived from the nonpathogenic Rhodobacter sphaeroides
[30]. The crystal structure of the TLR4-MD2 complex
with bound eritoran was recently described, suggesting that
eritoranmechanismofactionlieswithinitsbindinginalarge
hydrophobic internal pocket in MD2 [31]. Hence, it acts as a
LPS antagonist, since it is unable to trigger the intracellular
signalling cascade leading to NFκB translocation to the
nucleus.
Consequently, eritoran blocks the in vitro production of
cytokines in human whole blood [32] and induces a down-
regulation of intracellular generation of pro-inﬂammatory
cytokines [33]. Pharmacodynamic studies demonstrated a
continuous eﬃcacy with every 12 hours intermittent infu-
sion of the drug [34].
As for E5531, eritoran reportedly decreases clinical signs,
biological parameters, and inﬂammatory response induced
by endotoxin in healthy volunteers [35]. Eﬃcacy of various
doses of eritoran, ranging from 50mcg to 250mcg, was
assessed, while subjects were challenged with 4ng/kg LPS.
All eritoran doses achieved statistically signiﬁcant reductions
in elevated temperature, heart rate, C-reactive protein levels,
white blood cell count, TNFα and IL-6 levels. In the
higher doses groups (>100mcg/kg), eritoran also statistically
blunted the LPS-induced clinical signs such as fever, chills,
headache, myalgia, and tachycardia.
A trend toward decreased mortality was observed in
a phase II randomised controlled trial [36]. This study,
conducted in North America, recruited 293 patients who
were randomised to 3 groups: Eritoran high dose (105mg),
Eritoran small dose (45mg/d), or placebo. Actually, eritoran
at a dose of 105mg/d administered every 12 hours for 6
days, decreased mortality from 56,3% to 33.3% in patients
with high risk of mortality, as assessed by the Acute
Physiology and Chronic Health Evaluation II (Apache II)
Score. A large ongoing phase III randomised, double-blind,
placebo-controlled study is therefore recruiting patients with
suspected or proven infection, criteria for the systemic
inﬂammatoryresponsesyndromeandatleast1sepsis-related
organ dysfunction. Baseline APACHE II score must range
between 21 and 37. Treatment has to be started within 12
hours after the onset of organ failure. We expect the trial to
be completed by the end of 2010.
Eritoran could also modulate sepsis driven organ dys-
function such as cardiac depression and vasodilation, 2
frequent symptoms encountered in severe sepsis and septic
shock. Indeed, while the expression of TLR4 on cardiac
myocytes is known for years [37], the use of eritoran recently
helped identify, in animal models, the role of TLR4 and
intra-cellular signalling as one of the mechanism involved
in sepsis-related cardiac dysfunction [38]. After 6 hours
exposure to LPS, isolated cardiac myocytes from C3H/HeN
mice (a normally LPS susceptible strain) develop a reduced
sarcomere shortening amplitude and prolonged duration of
relaxation. The addition of 2μg/mL eritoran to the cultured
medium leads to a reduced eﬀect of LPS on all monitored
contractileparameters.Eritoranfurtherpreventsattenuation
of contractility observed in LPS treated isolated aortic rings
fromthesemice[39].Takentogether,thosedatareinforcethe
ideathatthismoleculecouldhelptreatingpatientwithsevere
sepsis, beyond its role in preventing cytokine production by
immune cells.
Eritorancouldalsomodulateothernoninfectiousdisease
processes, using the TLR4 pathway. Actually, in a model
of myocardial ischemia-reperfusion syndrome in C57BL/6
mice, the use of eritoran resulted in smaller infarct,
decreased JNK phosphorylation, NFκB translocation, and
cytokine production [40]. Because of the well-described
increased level of endotoxemia in patients undergoing
cardio-pulmonary bypass and the just-mentioned eﬀects of
eritoran on the heart and large vessels, eritoran eﬃcacy
was assessed in a double-blind, randomised, ascending
dose, placebo-controlled trial in patients undergoing cardiac
surgery [41]. While no statistically relevant diﬀerence could
be observed in various inﬂammatory parameters, no signiﬁ-
cant safety concern was identiﬁed.
4. Resatorvidor TAK 242
TAK 242, or ethyl-(6R)-[N-(2-chloro-4-ﬂuorophenyl] sul-
famoyl] cyclohex-1-hene-1-carboxylate, identiﬁed by Takeda
pharmaceuticals, is a small compound developed to inhibit
inﬂammatory mediators production [42]. It initially was
demonstrated to decrease NO and various cytokines produc-
tion in LPS stimulated mouse macrophages, as well as in a
mice endotoxin model [42]. A further study demonstrated
its ability to inhibit intracellular signalling, with decreased
MAPkinases phosphorylation and IκB degradation, without
any interference with LPS binding to TLR4 [43]. Since
the eﬀects of ligands to other TLR were not aﬀected, this
eﬀect was speciﬁc for TLR4. Similar results were obtained
using human peripheral blood mononuclear cells (PBMCs),
monocytes and macrophages. While the action of TAK 242
in the intracellular domain of TLR4 is known for some times
[44],Takashimaetal.onlyrecentlydemonstratedTAK242to
inhibit TLR4 signalling by direct binding to a speciﬁc amino
acid (Cys747) in the TLR4-intracellular domain [45].
In a mice intraperitoneal endotoxin model, intravenous
TAK 242 inhibits the pro-inﬂammatory response and
prevents lethality in a dose-dependent manner [46]. Of
importance, treatment up to 2 hours after the LPS challenge
results in similar beneﬁts. In an intravenous endotoxemia
model using conscious guinea pig, the use of TAK 242 allows
better hemodynamic control, decreased level of HMGB-1
and a dose-dependent improved survival [47].4 Mediators of Inﬂammation
In phase 1 clinical studies in normal healthy subjects
given concomitant endotoxin, TAK 242 inhibited the pro-
duction of cytokines TNFα, IL-6 and IL8. Nonclinically
signiﬁcanthaemolysisandincreasesinmethemoglobinlevels
were occasionally observed. A large, multicentre, multina-
tional, randomised, double-blind, placebo-controlled study
was initiated in September 2005 (http://clinicaltrials.gov/.
NCT00143611). 18-year-old or older subjects with severe
sepsis and related respiratory or cardiovascular failure were
eligible. The study was ended prematurely after the DSMB
determined there was insuﬃcient cytokine suppression in
the 150-subject analysis within stage 1 of the study. Another
study was planned but unfortunately never started based on
business decision (http://clinicaltrials.gov/. NCT00633477).
While further development in sepsis patient is unlikely, the
potential beneﬁt of TAK 242 in other TLR4 related diseases,
such as autoimmune diseases, has to be assessed.
5. ChloroquineandOther TLR 9 Antagonists
While the major signalling pathway of LPS lies within its
binding to the MD2/TLR4 complex, several reports have
indicated that endotoxin may enter immune cells [48]
and localize in the Golgi apparatus and other vesicles
[49]. This was further conﬁrmed in human PBMC [50].
Therefore, intracellular receptors and medication interfering
with those receptors or with intracellular traﬃcking could be
of importance.
Actually, TLRs that recognize nucleic acids, such as
TLR3, 7, 8, and 9, are conﬁned to endocytic compartment
where they encounter ligands internalised through receptor-
mediated endocytosis or phagocytosis. Upon stimulation
of cells, TLR9, for instance, appears to be traﬃcking from
endosome to lysosome where it undergoes proteolytic
maturation in an acidic environment to become competent
[51]. Asparaginase endopeptidase looks critical for this
phenomenon [52].
Recently, Plitas et al. demonstrated in a TLR9−/−
mice model of cecal ligation and puncture-(CLP-) related
peritonitis, an increased bacterial clearance, decreased serum
cytokineproductionandincreasedgranulocytesinﬂuxinthe
peritoneum as compared to wild type animals [53]. Using
an inhibitory CpG sequence that blocks TLR9 just before the
CLP, they also demonstrated an improved survival in wild
type animals.
Taken together, those data suggest that medication able
at blocking TLR9 maturation or signalling could be of
interest in sepsis. Actually, chloroquine, a drug used in
infectious(malaria)andinﬂammatory(SLE)diseases,blocks
traﬃcking and, or acidiﬁcation of the endosome. It is
known for years that chloroquine decreases the in vitro
response to various pro-inﬂammatory stimuli such as LPS
[53] or CpG oligonucleotide. In vivo, chloroquine protected
mice from lethal doses of LPS or CpG through a decrease
of proinﬂammatory cytokine release [54]. Using murine
macrophage ANA-1 cells, the authors further demonstrated
with chloroquine a decreased expression of TLR4 and 9
m R N Ae x p r e s s i o n sa sw e l la sab l o c k a d eo fN F κBa n d
AP1 activation. Chloroquine demonstrates its positive eﬀects
when used prior to the induction of CLP, but also up to
6h o u r sa f t e r[ 55]. In this experiment, decreased splenic
apoptosis was observed, suggestive of a mechanism that
improves sepsis-induced immune paralysis. Renal function
was also improved.
Hence, chloroquine may act at 2 diﬀerent levels: down-
regulation of TLR4 expression and interfering with the
intracellular traﬃcking of LPS through its action on TLR9.
Of notice, chloroquine also interferes with other TLRs that
are internalised and function through endosomal pathway.
Whether its actions in polymicrobial sepsis are TLR9 speciﬁc
or nonspeciﬁc has still to be elucidated.
Because of its excellence tolerance, further clinical devel-
opment in sepsis and critical care looks promising.
6.Ketamine
Because of its eﬀects on hemodynamic, ketamine, an
intravenous anaesthetic agent is widely applied in critical
care for induction of anaesthesia or even for maintenance
of sedation. Anti-inﬂammatory eﬀects of ketamine are
widely demonstrated in various in vitro animal and human
models. The ketamine eﬀects on TLR expression are less
known. In a rat model of intravenous LPS stimulation,
TLR4 expression and NFκB activation were decreased in
the intestine of ketamine-treated animals [56]. Using the
same model, the authors demonstrated identical results in
the lungs [57] .I nar a tm o d e lo fC L P ,t r e a t m e n tw i t h
ketamine after the procedure decreased intestine levels of
pro-inﬂammatory cytokines, as well as NFκBa c t i v a t i o n
and TLR4 and 2mRNA expression, when compared to rats
treated with saline [58]. Again, similar results were observed
in the lungs, with decreased secretion of pro-inﬂammatory
cytokines,decreasedactivationofNFκBanddecreasedTLR2,
and 4mRNA expressions [59]. Doses of ketamine used in
these various experiments (up to 10mg/kg) are far beyond
doses used in clinical settings. Mechanisms of action of
ketamine were studied in cultured murine macrophage cell
line Raw264.7. Not only does ketamine interfere with LPS
binding to LBP, but it also decreases phosphorylation of
various kinases involved in the TLR4 intracellular signalling
[60]. Likewise, ketamine-treated macrophages, stimulated
with lipoteichoic acid, a TLR2 agonist, produced less TNFα
and IL-6. This results from decreased phosphorylation of
ERK1/2, an upstream protein kinase for activating inhibitor
of NFκB( I κB) kinase (IKK), leading to decreased NFκB
translocation to the nucleus [61].
Clinical relevance of those results has to be assessed for
patients with sepsis or for patients sedated with ketamine.
7.Nicotine
Since the description of the so-called cholinergic anti-
inﬂammatory pathway [62], nicotine and analogues were
studied in various cultured cells and animal models of
sepsis, pancreatitis, and ischemia-reperfusion syndrome.
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LPS-induced inﬂammatory response in healthy volunteers
[63]. While the nicotinic acetyl-choline receptor, speciﬁcally
those comprised only of alpha-7 subunits, on myeloid cells
are required for this eﬀect [64], the precise intra-cellular
mechanism of action is not fully elucidated. Activation of the
JAK2-STAT3 pathway and suppression of the NFκBa c t i v i t y
atthetranscriptionallevelareimplied[65,66].Recently,Kox
et al. conﬁrmed the reduced cytokine production in human
PBMC treated with nicotinic analogues, whatever the stimu-
lated TLR [67]. This eﬀect is likely mediated by JAK2/STAT3
signalling. Interestingly, they also demonstrated with GTS-
21, a potent α-7 selective partial agonist, modulation of
TLR expression after LPS stimulation; TLR2 up-regulation
was decreased while TLR4 up-regulation was completely
abolished.Thisfurtherconﬁrmsanearlierexperimentwhere
nicotine induced a downregulation of TLR4 expression
on human monocytes, with or without concomitant LPS
stimulation [68].
All those data strongly support a potential role for
nicotinicagoniststomodulatecytokineproductionaswellas
toll like receptor expression in severe sepsis and septic shock.
Further investigations are required.
8. Opioids
For years, we know that TLRs are expressed in the central
nervous system (CNS): while microglia express a wide range
of TLRs, astrocytes and oligodendrocytes mainly express
TLR2 and 3 [69]. Interestingly, enhanced TLR expression
is observed in inﬂamed CNS tissues. We also know that
morphine and opioid derivates display, beyond their role
in pain control, important immunomodulatory eﬀects,
characterizedinanimalaswellasinhumanstudies(reviewed
in [70]).
TLRs are a key link between the innate immune system
and the CNS. Furthermore, several reports demonstrate
the involvement of TLR in various types of pain (chronic,
neuropathic and inﬂammatory) as well as in morphine
tolerance (reviewed in [71]). Very interestingly, TLR4 was
demonstrated to be of particular importance, since select
opioids may nonstereoselectively inﬂuence its signalling,
while having no eﬀects on classical morphine receptors [72].
Indeed, morphine-3-glucuronide, a morphine metabolite
with no opioid receptor activity, displays signiﬁcant TLR4
activity.
Those data raise at least 2 hypotheses; ﬁrst, modulation
of TLR, in particular TLR4, could be a strategy in the man-
agement of chronic pain. Secondly, the use of morphine and
other opioids in the critical care setting could interfere with
the response to inﬂammatory stimuli such as LPS. Again,
clinical consequences of this warrant further investigation.
9. Statins
Beyond their well-demonstrated lipid lowering eﬀects
resulting in clinical beneﬁts in cardiovascular diseases, 3-
hydroxy3-methylglutaryl-(HMG-) coenzyme A inhibitors,
or statins, display pleiotropic eﬀects. Statins inhibit NF-κB
activation and the subsequent pro-inﬂammatory cytokines
such as TNFα and IL-6 production. They also blunt
endotoxin related activation of cultured human coronary
endothelial cells and human PBMC. While these eﬀects are
known for years, Methe et al. only recently reported an
eﬀect of statins on TLR4 expression [73]. They demon-
strated a dose dependent decrease of TLR4 mRNA and
protein expression in CD14+ human monocytes incubated
in vitro with simvastatin or atorvastatin. They observed a
similar eﬀect in vivo, in 12 normocholesterolemic healthy
volunteers. Four weeks treatment with atorvastatin 20mg/d
resulted in a 36.2% reduction in TLR4 expression on CD14+
monocytes. Intracellular mechanism of action could include
inhibition of protein geranylgeranylation and farnesylation
leading to the hypothesis that proteins of the Ras family and
the phosphoinositide 3-kinase/protein kinase Akt-pathway
are of importance in mediating the TLR4 expression [73]. In
accordance with those results, simvastatin 80mg/d for 4 days
decreasedtheendotoxin-relatedupregulationofTLR2and4,
in 20 healthy volunteers exposed to 2ng/kg intravenous LPS
[74]. This expression modulation was also demonstrated in
moderate chronic heart failure patients [75]. Interestingly,
statins were demonstrated to be most active in reducing
the risk of cardiovascular diseases in patients carrying the
G allele for TLR [76]. In human embryonic kidney (HEK)
293-CD14-MD2 cell transfected with various TLR4 variants,
Hodgkinson and Yee demonstrated that TLR4 variations
and statins have an additive inhibitory eﬀect on TLR4-
mediated response to LPS, in term of NFκB activation and
cytokine production [77]. They further emphasize the role
of geranylgernayltransferase and Rho-kinase inhibition to
explain the statin intracellular mechanism of action.
Another hypothesis on the eﬀect of statin on TLR
expression is its potential inﬂuence on TLR4 membrane
traﬃcking in treated subjects because of altered cholesterol
rich membrane domains, as observed in brain plasma
membranes [78].
The potential of statins as an adjunctive therapy for
severe sepsis is currently evaluated in various clinical trials.
Actually, a recent meta-analyse suggests that statin treatment
may be associated with a beneﬁcial eﬀect in treating and
preventingvariousinfections[79].Becauseofthepresenceof
heterogeneity and publication bias further randomised trials
are required.
10.VitaminD3andAnalogues
Beyond its important role as a regulator of the calcium-
phosphate homeostasis, the hormonally active form of
vitamin D displays numerous eﬀects on the immune system
[80]. Vitamin D3 and analogues were demonstrated to be
protective in a mice model of intraperitoneal endotoxin
shock [81]. This positive eﬀect was also demonstrated
on coagulation parameters in a rat model of CLP-related
sepsis model [82]. Regulation of thromboxane A2 and free
radical formation were initially proposed as mechanisms of
action [83]. We now know that TLR activation in human
monocytes and macrophages leads to an upregulation of6 Mediators of Inﬂammation
the vitamin D receptor (VDR) and the vitamin-D-1 hydrox-
y l a s eg e n ee x p r e s s i o n[ 83]. These authors also demonstrate
that, in presence of vitamin D, this up-regulation leads to
increased expression of the cathelicidin mRNA. This cationic
antimicrobial peptide is stored in secretory granules and is
processed during or after secretion into its mature form,
LL-37 [84]. This α-helical peptide displays several functions,
including killing of pathogens, neutralizing LPS, or acting as
a chemo attractant [85].
The eﬀect of vitamin D on TLR surface expression is
inconstantly reported. On one hand, vitamin D3 was shown
to decrease TLR2 and 4 mRNA and protein expression in
a time- and dose-dependent fashion in human monocytes
[86]. This led to a decreased production of cytokines
a n dt i s s u ef a c t o rp r o d u c t i o na sw e l la sad e c r e a s e dN F κB
translocation to the nucleus after LPS or LTA stimulation.
Interestingly, the eﬀect of vitamin D3 on TLR expression was
VDR-dependent. On the other hand, TLR expression and
MD2 expression were not aﬀected by vitamin D3 in cultured
human endothelial cells (HMEC) [87]. Nonetheless, vitamin
D3 pretreatment resulted in decreased LPS-induced IL-6 and
IL-8 production and blocked NFκB activation.
Taken together, all these data suggest a clear relationship
between vitamin D and the TLR pathway and its biological
outcomes. Actually, compared to healthy controls, critically
ill patients with sepsis had lower levels of serum hydroxyl-
vitamin D and LL-37 [88]. It looks therefore logical to assure
a normal vitamin D serum level in patients with severe sepsis
or septic shock. This should however further be assessed in a
randomised trial.
11.Other Molecules
Because of their strong antisecretory eﬀects, proton pump
inhibitors (PPI) are widely used to treat gastric and
duodenal ulcer as well as reﬂux oesophagitis. They were
also reported to display anti-inﬂammatory and immune
properties. For instance, they attenuate polymorphonuclear-
dependent gastric mucosal inﬂammation by interfering with
NFκB activation in gastric epithelial cells and vascular
endothelial cells [89]. They also modulate the cytosolic
concentration of calcium in polymorphonuclear cells. In
a study using endotoxin-stimulated 293hTLR4/MD2-CD14
cells, lansoprazole modulated intranuclear transfer of NFκB
and stimulated the expression of Suppressor of cytokine
signalling-1 (SOCS1), a negative feed back gene involved in
excessive LPS stimulation [90]. Therefore, the use of PPIs
could modulate the intracellular cascade after TLR4 stimu-
lation. However, those results warrant further investigations
in other cell types as well as in vivo.
Lidocaine, a widely used local anaesthetic, has been
reported to attenuate cytokine-induced cell injury and
inhibit iNOS expression in activated murine macrophage
[91]. To further investigate this latter eﬀect, Lee et al
demonstrated that it attenuates the up-regulation of TLR4
expression, NF-κB, and some MAPKinases, in murine
macrophages stimulated with LPS [92]. Voltage sensitive
sodium channels, if present in macrophages, could be
involved in the modulation of TLR and downstream signals
modulation. While the use of lidocaine was demonstrated to
attenuate acute lung injury in rats exposed to intraperitoneal
doses of endotoxin [93], clinical relevance in humans
remains to be established.
Glycine, a α-amino acid that acts as an inhibitory
neurotransmitter in the central nervous system, also exerts
immune-modulatingactionsviastimulationofglycine-gated
chloride channels in immune cells. Glycine inhibits LPS-
binding protein (LBP) mRNA expression in the liver mice
challenged with LPS, also decreases TLR4 mRNA expression,
and decrease activity of NFκBi nk u p ﬀer cells of those
animals[94].Becauseofinconsistentresultinvariousanimal
models, the clinical use of glycine as an immune-modulating
agent in sepsis remains to be elucidated.
12. Conclusions
The TLR4 signalling pathway leading to lipopolysaccharide-
mediated NF-κB activation constitutes an important ther-
apeutic target for sepsis therapy. Various molecules are
involved in TLR4 membrane regulation and could behave
as new adjuvant therapies able to weaken the deleterious
eﬀects of exaggerated host response to infection. Most of
those are not yet exploited and additional laboratory and
clinical investigations are required to conﬁrm their expected
inﬂuence. Many studies have documented capacities of new
drugs to regulate TLR4 signalling and expression. For most
of them, mechanisms underlying this action still need to be
straighten out. Moreover, clinical implications remain to be
corroborated, especially for those medications already used
for other indications, such as ketamine. A better knowledge
of TLR4 regulation molecules will be crucial to control host
toinfectionreactionandavoidthedetrimentalconsequences
of sepsis. Among the drugs looking promising, eritoran, a
lipidAanalogue,isundergoingalargephaseIIIclinicaltrial.
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